Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I multiple ascending-dose study of ICA 105665 in healthy volunteers.

Next Previous
X
Search
Trial Profile

Phase I multiple ascending-dose study of ICA 105665 in healthy volunteers.

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 16 Sep 2010

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ICA 105665 (Primary)
  • Indications Epilepsy
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Neusentis

    • Most Recent Events

    • 13 Sep 2010 Icagen has completed the conduct of the study at daily doses of 500mg and 600mg for a period of 7 days, according to a company issued media release. Analyses of the complete data are ongoing.
    • 27 Nov 2009 Results will be presented at the 63rd Annual Meeting of the American Epilepsy Society.
    • 17 Apr 2009 Results have been presented at the Antiepileptic Drug Trials X Conference in Coral Gables, Florida.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top